Aslan hires Kobayashi to add IL-13 clinical trial expertise 

Aslan CMO Kenneth Kobayashi (Aslan)

Aslan Pharmaceuticals has named Kenneth Kobayashi as its chief medical officer. The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Kobayashi joined Dermira one year ago to work on a phase 3 program for lebrikizumab, an anti-IL-13 that emerged from phase 2 looking like a potential challenger to Sanofi and Regeneron’s blockbuster Dupixent. However, the phase 2 data attracted Lilly, which closed its $1.1 billion takeover of Dermira earlier this year.

With Lilly taking lebrikizumab forward, Kobayashi has looked elsewhere for employment and landed on a project well suited to his background. Like lebrikizumab, Aslan’s lead candidate ASLAN004 is an anti-IL-13 antibody.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Aslan is one of the little guys in the race to bring rivals to Dupixent to market. Aslan joined the race in 2014 when it struck a deal with CSL to put ASLAN004 through an Asian-centered R&D program. Last year, Aslan revised the deal to claim the full global rights to ASLAN004.

A phase 1 trial of ASLAN004 in patients with moderate-severe atopic dermatitis got underway last year, only for the pandemic to force Aslan to pause enrollment. Despite the setback, Aslan expects to move ASLAN004 into a global phase 2b program next year. The program will go some way to showing whether Aslan has a chance at developing a drug to rival Dupixent and lebrikizumab.

In Kobayashi, Aslan has hired a researcher with experience designing late-phase trials of anti-IL-13 antibodies in atopic dermatitis. In the short period between appointing Kobayashi and selling up to Lilly, Dermira started four phase 3 atopic dermatitis trials. A fifth phase 3 trial in the indication got up and running after Lilly closed the takeover in February.

Kobayashi landed a position working on the lebrikizumab phase 3 program on the strength of a long career in dermatology. Leo Pharma, another company with an anti-IL-13 drug in its pipeline, gave Kobayashi his first role in industry in 2008. In 2015, Kobayashi joined Novartis, where he spent several years working on drugs against targets including IL-17C. 

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.